Sai Life Sciences Ltd
Sai Life Sciences Q2 Results 2026 (FY27): Revenue ₹659 Cr, PAT ₹98 Cr
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹659Cr
- Net profit
- ₹98Cr
- Margin
- 28.3%
Guidance rank: #64 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Sai Life Sciences Ltd Q2 FY27 key numbers
- Revenue
- EBITDA for Q2 FY27: ₹187 Cr (28% margin), up 20% YoY.
As stated in Sai Life Sciences Ltd's Q2 FY27 investor presentation · published 5 Nov 2026. Reported figures, not investment advice.
Based on Sai Life Sciences Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Revenue for Q2 FY27: ₹659 Cr, a 23% year-on-year (YoY) growth from ₹537 Cr in Q2 FY26 (Page 8, 30). Q2 FY27 EBITDA: ₹187 Cr, 28% margin, 20% YoY growth.
From Sai Life Sciences Ltd's Q2 FY27 earnings-call transcript · updated 5 Nov 2026.
How did Sai Life Sciences' revenue grow in the September 2026 quarter?
- Revenue for Q2 FY27: ₹659 Cr, a 23% year-on-year (YoY) growth from ₹537 Cr in Q2 FY26 (Page 8, 30).
- EBITDA for Q2 FY27: ₹187 Cr (28% margin), up 20% YoY (Page 8, 30).
- PAT for Q2 FY27: ₹98 Cr, up 17% YoY (Page 8, 30).
- Material margin for Q2 FY27: ₹484 Cr, 22% YoY growth (Page 8).
- Capex incurred in Q2 FY27: ₹358 Cr, part of ₹621 Cr for H1 FY27 (Page 8, 7, 12).
2 more points from Sai Life Sciences Ltd's call on revenue
Create a free account to keep reading this call
What happened to Sai Life Sciences' margins in Q2 FY27?
See what Sai Life Sciences Ltd said on profitability & margins — free account, 30 seconds.
What capex is Sai Life Sciences planning?
- Capex spend for H1 FY27 was ₹621 Cr, with ₹358 Cr spent in Q2 FY27.
- Overall capex projection for FY27 is ₹1,100 to ₹1,300 Cr.
- Capacity and capability expansion program is on track.
- Commenced operations with first end-to-end integrated collaboration onboarded last quarter; expected fully functional in Q3 FY27.
- Converted another large pharma relationship into a similar strategic engagement; discussions underway with other large pharma for expanding integrated outsourcing model.
2 more points from Sai Life Sciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Sai Life Sciences raising money or cutting debt?
See what Sai Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Sai Life Sciences' order book?
See what Sai Life Sciences Ltd said on order book & pipeline — free account, 30 seconds.
Sai Life Sciences Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the table below.
Sai Life Sciences Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 659 |
| Operating profit (EBITDA) | 186 |
| Operating margin | 28.3% |
| Profit before tax | 131 |
| Net profit (PAT) | 98 |
| EPS (₹) | 4.63 |
Source: Sai Life Sciences Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹554 Cr, net profit ₹73 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sai Life Sciences Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call →
- Q1 FY26 earnings call analysis →
Earlier calls (2)
Others in Pharmaceuticals & Biotechnology this season
- Ipca Laboratories (Q2 FY27)
Volume-led growth in pain segment is around 8-9%, with price growth at 4-4.5%. Key concall takeaways from Ipca Laboratories Ltd's Q2 FY27 earnings call — and…
- Gland Pharma Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹18,336 million, a 23% YoY increase from ₹14,869 million in Q2 FY26 (Page 5). Key investor presentation takeaways from Gland Ph
- OneSource Specialty Pharma (Q2 FY27)
. Key concall takeaways from OneSource Specialty Pharma Ltd's Q2 FY27 earnings call — and how it ranks against sector peers.
- Supriya Lifescience (Q2 FY27)
Q2 FY27 revenue from operations: INR 2,063.0 Mn, a 3.2% YoY increase from INR 1,998.3 Mn in Q2 FY26 (Page 9). Key investor presentation takeaways from Supriya L
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sai Life Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sai Life Sciences Ltd Q2 FY27 results?
Revenue for Q2 FY27: ₹659 Cr, a 23% year-on-year (YoY) growth from ₹537 Cr in Q2 FY26 (Page 8, 30). Q2 FY27 EBITDA: ₹187 Cr, 28% margin, 20% YoY growth.
What is Sai Life Sciences Ltd share price analysis?
Sai Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 92.2 with a market cap of ₹33,887 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sai Life Sciences Ltd planning capital expenditure?
Capex spend for H1 FY27 was ₹621 Cr, with ₹358 Cr spent in Q2 FY27.
Keep Sai Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.